• FAM83A Controls Mitochondrial Integrity in White Adipocyte D

  2026-05-06

  This study identifies FAM83A as a crucial regulator of mitochondrial maintenance and white adipocyte differentiation. Using targeted gene knockdown via an adipocyte-specific delivery system, the authors reveal that FAM83A loss impairs lipogenesis and mitochondrial function, implicating it as a potential target for obesity and metabolic disease research.

• EPZ-6438 (SKU A8221): Reliable EZH2 Inhibition for Epigeneti

  2026-05-05

  This article addresses common laboratory challenges in cell viability and cytotoxicity assays, focusing on the practical deployment of EPZ-6438 (SKU A8221) as a selective EZH2 inhibitor. By exploring real-world scenarios, it demonstrates how EPZ-6438 enhances workflow reproducibility and data quality for epigenetic cancer research. Comprehensive Q&A blocks provide actionable insights and evidence-backed solutions for biomedical researchers.

• Cardiogreen (Indocyanine Green): Translational Workflows & P

  2026-05-05

  Cardiogreen (Indocyanine Green) bridges diagnostic precision and therapeutic innovation, fueling both vascular imaging and advanced photodynamic therapy. Learn how this dye, supplied at high purity by APExBIO, empowers reproducible workflows and addresses common experimental pitfalls in translational research.

• GSTA1 Drives Glutathione Depletion and Liver Injury in α-Ama

  2026-05-04

  This study uncovers a paradoxical role for GSTA1 in α-amanitin-induced hepatotoxicity, showing that upregulation of this hepatic antioxidant enzyme accelerates glutathione depletion and oxidative stress. These findings reposition GSTA1 as a direct pathogenic factor and potential therapeutic target for acute amatoxin-mediated liver injury.

• Elobixibat Hydrate: Applied Workflows for IBAT Inhibition St

  2026-05-04

  Elobixibat hydrate is a powerful ileal bile acid transporter inhibitor, enabling researchers to precisely modulate enterohepatic circulation for GI and metabolic disease models. This article details evidence-based protocols, troubleshooting strategies, and advanced use-cases that set Elobixibat hydrate apart for translational and bench workflows.

• PPM-18: Precision iNOS Inhibition for Inflammation Research

  2026-05-03

  PPM-18 empowers researchers with targeted, reproducible inhibition of iNOS via selective NF-κB pathway modulation. Its robust performance in inflammation and sepsis models—together with protocol-friendly solubility and stability—distinguishes it as an advanced tool for dissecting immune responses and optimizing anti-inflammatory workflows.

• Etoposide (VP-16): Applied Workflows in Cancer Research

  2026-05-02

  Etoposide (VP-16) is a gold-standard DNA topoisomerase II inhibitor, powering precise DNA damage and apoptosis assays across diverse cancer models. This guide translates literature-backed protocols, troubleshooting tactics, and comparative insights to help researchers optimize every stage of their experimental workflow with APExBIO’s Etoposide.

• Elobixibat Hydrate: Bridging Bile Acid Modulation to Metabol

  2026-05-02

  This thought-leadership article explores the mechanistic depth and translational promise of Elobixibat hydrate, positioning it as a pivotal tool for researchers targeting gastrointestinal motility and metabolic disorders. Grounded in the biology of bile acid transport and supported by comparative pharmacological perspectives, we outline strategic guidance for experimental and clinical teams, while addressing the evolving competitive landscape. This analysis uniquely expands on existing literature by integrating mechanistic insight, protocol recommendations, and a forward-looking vision for metabolic and inflammatory research.

• Intranasal Sumatriptan as First-Line Therapy for Pediatric M

  2026-05-01

  This study evaluates the use of intranasal sumatriptan as a first-line intervention for acute migraine in pediatric emergency settings. Results indicate significant pain reduction, shorter ED stays, and reduced costs compared to intravenous therapies, suggesting an effective alternative for children and adolescents presenting with refractory headaches.

• NSAID-Induced Cytotoxicity in Canine Osteosarcoma Cells: In

  2026-04-30

  This study systematically evaluated the cytotoxic and apoptotic effects of deracoxib and piroxicam on canine osteosarcoma cell lines in vitro. While both NSAIDs reduced tumor cell viability at high concentrations, neither induced apoptosis, and the concentrations required for efficacy exceeded clinically achievable plasma levels—highlighting both their mechanistic limitations and the need for alternative antiproliferative strategies.

• Lypressin acetate: Vasopressin Analog for Diabetes Insipidus

  2026-04-30

  Lypressin acetate is a pig-derived vasopressin analog with robust antidiuretic, vasopressor, and emerging antiviral properties. It is well-validated for use in the treatment of diabetes insipidus and in laboratory vasoconstriction research. Its quantitative activity and rapid plasma half-life are supported by peer-reviewed evidence and product benchmarks.

• Ertugliflozin (PF-04971729): Scenario-Driven Lab Reliability

  2026-04-29

  This article provides practical, scenario-based guidance for researchers leveraging Ertugliflozin (PF-04971729), SKU A3715, in cell viability and renal glucose transport assays. It details validated strategies, comparative product insights, and protocol parameters—ensuring reproducibility and sensitivity for diabetes mellitus research workflows.

• Tariquidar (XR9576): Enhancing Drug Resistance Research Prec

  2026-04-29

  Tariquidar (XR9576) is a potent, selective P-glycoprotein inhibitor that enables precise dissection of drug efflux mechanisms in cancer chemoresistance studies. Its high affinity and unique solubility profile make it ideal for advanced transporter-mediated drug disposition assays, especially in challenging microenvironments mimicking tumor viscosity.

• Sumatriptan Succinate: Advanced Workflows for 5-HT1 Receptor

  2026-04-28

  Sumatriptan Succinate, a selective 5-HT1 receptor agonist, is redefining serotonergic and migraine research through rigorous, reproducible workflows. This article translates clinical and bench advances into actionable protocols, troubleshooting insights, and comparative strategies for leveraging APExBIO’s high-purity Sumatriptan across inflammation, neurovascular, and pediatric migraine models.

• Vincristine Sulfate (A1765): Reliable Solutions for Cancer R

  2026-04-28

  This article equips biomedical researchers and lab technicians with scenario-driven guidance for integrating Vincristine sulfate (SKU A1765) into cell viability, proliferation, and cytotoxicity assays. Drawing from real-world laboratory challenges and quantitative data, it demonstrates how APExBIO’s Vincristine sulfate enhances assay reproducibility, sensitivity, and workflow reliability in cancer research.

16389 records 1/1093 page Next 12345 下5页 Last page